Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Total Current Assets : €485.4 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Laboratorios Farmaceuticos Rovi's total current assets for the quarter that ended in Mar. 2024 was €485.4 Mil.

Laboratorios Farmaceuticos Rovi Total Current Assets Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Total Current Assets Chart

Laboratorios Farmaceuticos Rovi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

317.89

364.58

506.36

623.07

509.33

Laboratorios Farmaceuticos Rovi Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															631.59	637.97	567.06	509.33	485.42

Laboratorios Farmaceuticos Rovi Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Laboratorios Farmaceuticos Rovi's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	25.322	+	143.314	+	337.968	+	2.727
	=	509.3

Laboratorios Farmaceuticos Rovi's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	13.085	+	131.488	+	337.971	+	2.871
	=	485.4

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Laboratorios Farmaceuticos Rovi's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	13.085	-	254.881	+	0.75 * 131.488	+	0.5 * 337.971
=	25.8

Laboratorios Farmaceuticos Rovi Total Current Assets Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.